Portal Hypertension VII : Proceedings of the 7th Baveno Consensus Workshop: Personalized Care in Portal Hypertension / edited by Roberto de Franchis.

PART I) INTRODUCTORY LECTURES -- Chapter 1) Introduction: Baveno I to Baveno VII.... and Beyond -- Chapter 2) New Concepts in Risk Stratification -- Chapter 3) Clinical Stages and Ordinal Outcomes in Portal Hypertension -- Chapter 4) Lifestyle and Genetic Modifiers of Liver Disease Progression -- PART II) HVPG AS A GOLD STANDARD -- Chapter 5) HVPG as a Gold Standard: Accuracy Is Essential -- Chapter 6) Consensus Statements, Panel 1: HVPG as a Gold Standard -- PART III NONINVASIVE TOOLS FOR cACLD AND PORTAL HYPERTENSION -- Chapter 7) Results of the Baveno VII Questionnaire on the Use of Non-Invasive Tools for cACLD and Portal Hypertension -- Chapter 8) Compensated Advanced Chronic Liver Disease (cACLD) -- Chapter 9) Non-Invasive Detection of Clinically Significant Portal Hypertension with Liver Elastography -- Chapter 10) Varices and Screening Endoscopy -- Chapter 11) Liver Elastography for Prognostication and Monitoring Patients with Compensated Advanced Chronic Liver Disease -- Chapter 12) SpleenStiffness -- Chapter 13) Emerging Non-Invasive Markers: Imaging, Blood, and Liver Clearance Tests -- Chapter 14) Consensus Statements, Panel 2: Non-Invasive Surrogates for cACLD, CSPH, Varices -- PART IV) NEW SCENARIOS 1: INTRODUCTORY LECTURES: PROGRESSION AND REGRESSION OF CIRRHOSIS -- Chapter 15) Progression and Regression of Cirrhosis: The Histologic Perspective -- Chapter 16) Liver Fibrosis and Its Regression in the Context of Portal Hypertension -- Chapter 17) Angiogenesis and Progression of ACLD -- Chapter 18) Drugs to Modify Liver Fibrosis Progression and Regression -- PART V) NEW SCENARIOS 2 - MANAGEMENT OF ACLD AFTER REMOVAL OF THE PRIMARY ETIOLOGICAL FACTOR -- Chapter 19) Therapies for Alcohol-Related Liver Disease and for Non-Alcoholic Fatty Liver Disease -- Chapter 20) Management of ACLD after HBV-Suppression and HCV-Cure- Chapter 21) Consensus Statements, Panel 3: Management of ACLD after Removal/Suppression of the Etiological Factor -- PART VI) NEW SCENARIOS 3 - IMPACT OF NON-ETIOLOGICAL NOVEL THERAPIES IN THE COURSE OF CIRRHOSIS -- Chapter 22) Results of the Baveno VII Questionnaire on the "Impact of Non-Etiological Therapies in the Course of Cirrhosis -- Chapter 23) Statins in Compensated and Decompensated Cirrhosis: Approaching the Bedside -- Chapter 24) Anticoagulation for Portal Vein Thrombosis in Cirrhosis: an Evidence-Based Approach to When and How -- Chapter 25) Novel Approaches & Disease Modifiers to Alter the Course of Cirrhotic Portal Hypertension -- Chapter 26) Targeting the Gut Microbiome in Cirrhosis -- Chapter 27) Impact of Non-Etiological Novel Therapies in the Course of Cirrhosis - Consensus Statements of Panel 4 -- PART VII) CLINICAL SETTINGS 1 - PREVENTING (FIRST) DECOMPENSATION -- Chapter 28) Prevention of First Decompensation: Questionnaire -- Chapter 29) Definition of First Decompensation in Cirrhosis -- Chapter 30) Evaluation of the Impact of the Sole Presence of Infection (Without Accompanying Decompensation) in the Natural History of Compensated Cirrhosis- Chapter 31) Evaluation of the Role of Jaundice in the Definition of Decompensation in the Compensated Patients -- Chapter 32) Evaluation of the Role of Minimal Perihepatic Ascites, Minimal Hepatic Encephalopathy, and Bleeding due to Portal Hypertensive Gastroenteropathy in the Definition of Decompensation -- Chapter 33) Evaluation of the Role of Sarcopenia in the Definition of Decompensation of the Compensated Patient -- Chapter 34) β-blockers to Prevent Decompensation of Cirrhosis in Compensated Patients with Clinically Significant Portal Hypertension- Chapter 35) Evaluation of the Effect of CSPH, Reduction of HVPG, and Other Factors Predicting the First Decompensation in Cirrhosis -- Chapter 36) Preventing (First) Decompensation - Consensus Statements of Panel 5 -- PART VIII) CLINICAL SETTINGS 2 - ACUTE VARICEAL BLEEDING -- Chapter 37) General Management of Acute Variceal Bleeding -- Chapter 38) Risk Stratification and Prognostic Factors in Variceal Bleeding -- Chapter 39) Endoscopic Management: Classic and New Therapies -- Chapter 40) Preemptive TIPS (p-TIPS) -- Chapter 41) Management of Refractory Variceal Bleeding -- Chapter 42) Hepatic Encephalopathy and Acute Variceal Bleeding -- Chapter 43) Management of Coagulation in Acute Variceal Bleeding -- Chapter 44) Gastric Varices and Ectopic Varice -- Chapter 45) Special Settings: Acute Variceal Bleeding and Portal Vein Thrombosis in Cirrhosis -- Chapter 46) Clinical Settings 2 - Acute Variceal Bleeding - Consensus Statements of Panel 6 -- PART IX) CLINICAL SETTINGS 3 - PREVENTING FURTHER DECOMPENSATION -- Chapter 47) Concept of Further Decompensation and Recompensation -- Chapter 48) Prevention of Variceal Bleeding and Rebleeding -- Chapter 49) Prevention of Further Decompensation in Patients with Ascites -- Chapter 50) The Impact of Sarcopenia, Frailty, and Malnutrition on Further Decompensation -- Chapter 51) Preventing Further Decompensation. Consensus Statements of Panel 7 -- PART X) VASCULAR LIVER DISORDERS 1 - SPLANCHNIC VEIN THROMBOSIS -- Chapter 52) Portal Vein Thrombosis. Anticoagulation Versus Interventional Radiology -- Chapter 53) Staging of Portal Vein Thrombosis. Recurrent Thrombosis and Prognostic Factors for Recurrence in Non-Cirrhotic Non-Tumoral Portal Vein Thrombosis (PVT) -- Chapter 54) Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis -- Chapter 55) Splanchnic Vein Thrombosis - Consensus Statements of Panel 8 -- PART XI) VASCULAR LIVER DISORDERS 2 - OTHER ISSUES IN VASCULAR LIVER DISORDERS -- Chapter 56) Porto-Sinusoidal Vascular Disorder -- Chapter 57) Anticoagulation in Splanchnic Vein Thrombosis with and without Underlying Liver Disease -- Chapter 58) Medical Approach to Fontan Patients -- Chapter 59) Other Issues in Vascular Liver Disorders - Consensus Statements of Panel 9. .